New Non-invasive Ultrasound Device
Spencer Technologies Begins Shipping a New Digital Transcranial Doppler That Better Identifies Conditions Contributing to Stroke

SEATTLE, WA – APRIL 10, 2001 – Spencer Technologies has begun shipping its first major product, the TCD100M, a digital transcranial Doppler (TCD).  The ultrasound device features a unique, patented display that offers greater ease of use over current technology and has significant technical advantages.

The TCD100M Digital Doppler features patented FlowTrax™ signal acquisition and display technology.  This allows novice and expert users alike to easily identify the location of blood flow within the brain.

Reactions at medical professional meetings this year have been very encouraging.  The company has received numerous requests for product demonstrations, and is in the process of ramping up its U.S. sales effort, as well as preparing for sales in Europe this summer. 

The company’s promotional strategy is geared toward replacing its competitors’ worldwide, installed base of approximately 15,000 units containing the older, analog TCD technology. This will significantly expand the overall market by encouraging wider utilization of the digital TCD100M which is easier to learn and use.

According to Dr. Andrei Alexandrov, a neurologist on the Stroke Treatment Team at the University of Texas – Houston Medical School and Principal Investigator for the Phase II CLOTBUST stroke randomized clinical trial of ultrasound-enhanced thrombolysis with TPA for stroke, “It (the TCD100M) may be the first technology to make TCD easy-to-use for clinicians, particularly in the emergency situations or at bedside, and to help develop operator-independent TCD devices for non-invasive diagnosis and monitoring.”

Dr. Andrew Demchuk, a leading neurologist at the University of Calgary and a recent TCD100M purchaser comments, “Things are going great!  I’ve found training others how to use TCD much easier.  What a breeze!  We are already uncovering findings with Power M-Mode (Flowtrax) never before seen with standard TCD.”

Spencer Technologies has four additional products in its pipeline, all of which are based on the new digital TCD platform. These products address the detection, prevention, and treatment of conditions leading to stroke, brain hemorrhage, pulmonary embolism, and deafness.